Morgan Stanley raised the firm’s price target on Regeneron to $941 from $914 and keeps an Overweight rating on the shares. In offering a 2024 outlook for North American Biopharma, the firm says it expects four themes – diabesity, product cycles, policy and rates – to be in focus next year. At the stock level, the firm expects “another year of dispersion” and generally recommends investors continue to focus on companies that can deliver growth in the second half of the decade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
- Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
- Regeneron announces new, updated data for odronextamabn in R/R DLBCL
- Regeneron to host conference call
- Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes